Print

Purpose

This study is being done to understand how oncologists can engage a multidisciplinary team to help endometrial cancer survivors with obesity to engage in a weight management program and potentially start a weight loss medication. Obesity often impacts the future health and longevity of early-stage endometrial cancer survivors more than their cancer diagnosis. Patients will be referred to the KUMC OB/Gyn weight management clinic to discuss weight management options. - If patients decide to use medications for weight loss, then the study will collect data from their chart that is recorded as part of routine monitoring for patients on weight loss medications. - If patients decide not to use any medications, the study will monitor physical exam and lab data collected as part of their routine medical care. The study will also try to understand reasons why patients did or did not start using a weight loss medication.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • ≥18 years old - ECOG 0-2 - BMI ≥ 30kg/m2 - Completed surgical staging with no evidence of residual disease - Endometrioid endometrial adenocarcinoma, p53 wild type - Stage 1 - Undergoing active surveillance +/- brachytherapy

Exclusion Criteria

  • Unable to participate in behavior weight loss - Stroke, heart attack, end stage liver disease, or end stage kidney disease during the last 6 months. - Currently on a GLP-1 agonist - Currently on insulin

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Endometrial cancer survivors with weight management Survivors of low-risk early-stage endometrial cancer up to12 months post primary treatment with body mass index (BMI) ≥30 kg/m2
  • Behavioral: Weight loss with pharmacotherapy
    Patients will meet with a weight management specialist and discuss their options for weight loss including medications (GLP-1 agonist, naltrexone/bupropion, orlistat, or phentermine/topiramate) or bariatric surgery.
    Other names:
    • Weight loss medications
  • Behavioral: Weight loss without pharmacotherapy
    Participants not on medications will have their weight recorded at subsequent cancer surveillance or other routine medical visits

Recruiting Locations

University of Kansas Medical Center
Kansas City, Kansas 66160
Contact:
Principal Investigator
913-588-0885
mjavellana@kumc.edu

More Details

Status
Recruiting
Sponsor
University of Kansas Medical Center

Study Contact

Principal Investigator
913-588-0885
mjavellana@kumc.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.